• OPEN AN ACCOUNT
Indian Indices
Sensex
74,314.59 -21.86
( -0.03%)
Global Indices
Nasdaq
51,493.09 -621.02
(-1.19%)
Dow Jones
7,573.47 -33.26
(-0.44%)
Hang Seng
63,960.24 37.24
(0.06%)
Nikkei 225
10,694.45 36.32
(0.34%)
Forex
USD-INR
95.42 0.14
(0.14%)
EUR-INR
110.10 0.01
(0.01%)
GBP-INR
128.62 0.03
(0.02%)
JPY-INR
0.62 0.00
(-0.26%)

EQUITY - MARKET SCREENER

United Textiles Ltd
Industry :  Textiles - Cotton/Blended
BSE Code
ISIN Demat
Book Value()
521188
INE727E01012
27.3333333
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
0
6.83
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

picturehouse media ltd
Indoco Remedies soars after Goa plant clears UK MHRA cGMP inspection
Sep 10,2026
The inspection of the facility, which manufactures solid oral dosage forms, was conducted from 7 September 2026 to 9 September 2026. The UK MHRA's current Good Manufacturing Practices (cGMP) inspection concluded with no critical or major observations, indicating compliance with the regulator's applicable manufacturing standards.

Indoco Remedies is a fully integrated, research-oriented pharmaceutical company with a strong global presence. It develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. Top Indoco brands include Cyclopam, Febrex Plus, ATM, Rexidin M, Karvol Plus, Oxipod, Cital, Sensodent-K, Cital-Uti, Dropizin, Homide, Dentogel, Oxipod CV, Turbocort, Febrex, Cloben G, Tuspel LS, Noxa, MCBM 69, etc.

The company reported a consolidated net profit of Rs 64.99 crore in Q1 FY27 as against a net loss of Rs 35.79 crore in Q1 FY26. Revenue from operations rose 8.43% year on year to Rs 466.22 crore in the first quarter of FY27 from Rs 430.86 crore in the corresponding quarter last year.